IOncology

Breast cancer is the most common malignancy among women worldwide, with approximately 5% to 10% of patients carrying BRCA gene mutations. These patients often present with more advanced disease, face a higher risk of recurrence, and have poorer prognoses. For patients with germline BRCA-mutated (gBRCA) triple-negative breast cancer (TNBC), platinum-based chemotherapy remains the standard treatment but offers limited survival benefits and comes with significant side effects. Meanwhile, for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients, endocrine therapy combined with CDK4/6 inhibitors is the first-line standard treatment. However, the optimal therapy after progression on CDK4/6 inhibitors is still unclear. In this era of precision medicine, there is a pressing need for more effective treatments for gBRCA-mutated HER2-negative breast cancer. At the 2024 Cross-Strait Breast Cancer Forum and the Annual Academic Conference of the Fujian Medical Association Breast Disease Branch, Oncology Frontier invited Dr. Huiping Li from Peking University Cancer Hospital to discuss the latest progress in precision treatment for BRCA-mutated breast cancer.

Breast cancer is the most common malignancy among women worldwide, with approximately 5% to 10% of patients carrying BRCA gene mutations. These patients often present with more advanced disease, face a higher risk of recurrence, and have poorer prognoses. For patients with germline BRCA-mutated (gBRCA) triple-negative breast cancer (TNBC), platinum-based chemotherapy remains the standard treatment but offers limited survival benefits and comes with significant side effects. Meanwhile, for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients, endocrine therapy combined with CDK4/6 inhibitors is the first-line standard treatment. However, the optimal therapy after progression on CDK4/6 inhibitors is still unclear. In this era of precision medicine, there is a pressing need for more effective treatments for gBRCA-mutated HER2-negative breast cancer. At the 2024 Cross-Strait Breast Cancer Forum and the Annual Academic Conference of the Fujian Medical Association Breast Disease Branch, Oncology Frontier invited Dr. Huiping Li from Peking University Cancer Hospital to discuss the latest progress in precision treatment for BRCA-mutated breast cancer.

At the highly anticipated 2024 San Antonio Breast Cancer Symposium (SABCS), numerous groundbreaking studies in breast cancer treatment were unveiled. Among them, the Working Group for Gynecological Oncology (WSG) presented long-term survival data from the WSG ADAPT-HR+/HER2- early breast cancer chemotherapy cohort (Abstract No.: GS3-04). This study integrates clinical pathology, genomic testing, and endocrine therapy response to refine risk stratification for recurrence in HR+/HER2- patients. Oncology Frontier invited Dr. Jia Wang from The Second Affiliated Hospital of Dalian Medical University to provide insights and commentary on this significant research.

The 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee, hosted by the Chinese Anti-Cancer Association Breast Cancer Professional Committee (CBCS) and the Shanghai Anti-Cancer Association, and organized by the Breast Cancer Professional Committee of the Shanghai Anti-Cancer Association, was held from December 20 to 21, 2024, in Shanghai. On the afternoon of December 21, the 2025 CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines and Standards (Essentials), known as the "Little Red Book," was officially released. Oncology Frontier invited Dr. Jian Zhang, a key member of the guideline development team and expert from Fudan University Shanghai Cancer Center, to discuss updates on medical treatments for various breast cancer subtypes in the new edition.

In the field of immunotherapy for colorectal cancer (CRC), ADAR1, an essential RNA-editing enzyme, has gained significant attention in recent years. At the 2024 ESMO Asia Congress, Dr. Da Kang from Dr. Zhizhong Pan’s team at the Sun Yat-sen University Cancer Center presented their latest findings on ADAR1 expression in T cells and its impact on immunotherapy resistance in CRC (Abstract No. 95P). Digestive Oncology Frontier interviewed Dr. Da Kang at the conference to delve deeper into this groundbreaking research.

Previous Phase II NEOTAX study results demonstrated that neoadjuvant therapy with toripalimab combined with axitinib effectively downstaged inferior vena cava tumor thrombi in some patients with renal cell carcinoma (RCC), significantly improving perioperative outcomes. However, resistance to therapy remains a challenge for some patients, necessitating further investigation. At the 2024 ESMO ASIA Congress, Dr. Liangyou Gu and Dr. Yaohui Wang from the Department of Urology at the Chinese PLA General Hospital shared insights into overcoming treatment resistance, providing valuable strategies for improving patient prognosis. Urology Frontier invited Dr. Yaohui Wang to offer an in-depth perspective.

Epidermal growth factor receptor (EGFR) gene mutations are the most common oncogenic driver mutations in non-small cell lung cancer (NSCLC) patients in China, with a significantly higher incidence compared to Caucasian populations. At the recent ESMO Asia Congress 2024, Dr. Li Zhang from the Sun Yat-sen University Cancer Center presented results from the Phase II BOOSTER clinical trial investigating Becotarug (JMT101) combined with Osimertinib for the treatment of classic EGFR-mutant NSCLC patients. Oncology Frontier interviewed Professor Zhang to discuss the background and key findings of this study.

Facing the global challenge of breast cancer in women’s health, China is advancing the standardization and quality control of breast cancer diagnosis and treatment with unprecedented determination. At the recent 2024 Straits Breast Cancer Forum and the Annual Meeting of the Breast Disease Branch of the Fujian Medical Association, Oncology Frontier invited Dr. Fei Ma, Vice Chair and Secretary-General of the Breast Cancer Committee of the National Cancer Quality Control Center and a leading expert from the National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences. Professor Ma shared insights into the significant progress China has made in improving standardized breast cancer treatment and reducing disparities between urban and rural areas. He also discussed future directions for breast cancer quality control initiatives.

Precision treatment for HER2-positive breast cancer has long been a focal point and challenge in breast cancer research. Recently, the DTP study (Abstract No.: RF1-07), presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), offers new insights into addressing this challenge. This study aims to explore the efficacy and safety of combining durvalumab immunotherapy with dual-targeted therapy in the neoadjuvant treatment of early-stage HER2-positive breast cancer. The goal is to discover new diagnostic and therapeutic directions for HER2-enriched breast cancer driven by precision medicine. Oncology Frontier invited Professor Feng Jin fromThe First Affiliated Hospital of China Medical University and Dr. Xiaoman Jiang from The Second Hospital of Jilin University to provide an in-depth analysis and commentary on the DTP study.

With continuous advancements in immunotherapy research, significant progress has been made in improving survival outcomes for patients with non-small cell lung cancer (NSCLC). Recently, based on the results of the KEYNOTE-671 study, the National Medical Products Administration (NMPA) approved the PD-1 inhibitor pembrolizumab for perioperative treatment in patients with resectable stage II, IIIA, and IIIB NSCLC. What is the clinical significance of this newly approved indication for perioperative treatment in NSCLC? What key considerations should clinicians focus on in practice? How will perioperative immunotherapy for NSCLC evolve in the future?